- Company to Present at the 2006 UBS Global Specialty Pharmaceuticals
                                Conference -

    BOCA RATON, Fla., April 17 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce first quarter 2006
financial results on Wednesday, April 26, 2006, after market close. The
company will host a conference call and live webcast at 4:30 p.m. ET.
    The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1300154 or via the Nabi Biopharmaceuticals
website at http://www.nabi.com .  If you do not have Internet access, the
U.S./Canada call-in number is 800-798-2864 conference code 92481183, and the
international call-in number is 617-614-6206 conference code 92481183.  An
audio replay will be available for U.S./Canada callers at 888-286-8010
conference code 31267148, and for international callers at 617-801-6888
conference code 31267148.
    An archived version of the webcast will be available at the same
Internet address through May 3, 2006. The audio replay will also be
available through May 3, 2006. The press release will be available on the
company's website at http://www.nabi.com .
    UBS Global Specialty Pharmaceuticals Conference
    Dr. Henrik Rasmussen, Senior Vice President, Clinical, Medical and
Regulatory Affairs, will be presenting at the 2006 UBS Global Specialty
Pharmaceuticals Conference on April 24, 2006 at 4:00 ET at the Grand Hyatt
Hotel, Park Avenue at Grand Central Terminal, New York, New York. Dr.
Rasmussen will be providing a corporate overview and a review of the Gram-
positive program.
    Dr. Rasmussen's presentation will be webcast live at:
http://event.streamx.us/event/20060424 or can be accessed through our
website at
http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol-calendar .
    The webcast presentation will be available through May 24, 2006.
    About Nabi Biopharmaceuticals
    Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has three products on the market
today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin
(Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Gram-positive bacterial infections, hepatitis and transplant, kidney
disease (nephrology) and nicotine addiction. For a complete list of
pipeline products, please go to: http://www.nabi.com/pipeline/index.php .
The company is headquartered in Boca Raton, Florida. For additional
information about Nabi Biopharmaceuticals, please visit our website at:
http://www.nabi.com .

Link to this page:

  

http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.